Drugs / MT10107
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03796351 | Sep 2012 → Jan 2013 | — | Medy-Tox | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03908008 | Jan → May 2014 | — | Medy-Tox | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT10107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03796351 ↗ |
| Known as | Botulinum toxin type A | “MT10107 (Botulinum toxin type A)” NCT03908008 ↗ |
| Modality | Protein / enzyme biologic | “MT10107(botulinum toxin type A)” NCT03796351 ↗ |
| Route | Intramuscular | “by intramuscular injection” NCT03796351 ↗ |